EGFR Positive Lung Cancer
Symptoms, Doctors, Treatments, Advances & More

EGFR Positive Lung Cancer Overview

Save information for later
Sign Up

Learn About EGFR Positive Lung Cancer

View Main Condition: Non-Small Cell Lung Cancer (NSCLC)

What is the definition of EGFR Positive Lung Cancer?
EGFR, or epidermal growth factor receptor, is a protein that is important for proper cell growth and division. In some cases of non-small cell lung cancer, a mutation can cause EGFR to be overexpressed, resulting in uncontrolled cell growth. Roughly 15% of cases of non-small cell lung cancer in the United States involve an EGFR mutation.
What are the causes of EGFR Positive Lung Cancer?
The majority of EGFR mutations are somatic, meaning that changes in DNA occur during a person's lifetime instead of being inherited. These types of mutations may occur from smoking or secondhand smoke exposure, air pollution, asbestos or radon exposure, or exposure to certain metals or chemicals. EGFR mutations tend to affect certain populations more than others including people of Asian heritage, women, and individuals with lung adenocarcinoma. Less commonly, individuals can inherit a mutation in the EGFR gene known as T790M when they are born. This mutation can put those individuals at a higher risk for developing lung cancer.
What are the symptoms of EGFR Positive Lung Cancer?
Early EGFR positive lung cancer may not cause any symptoms. As the condition progresses, individuals may experience chronic cough, coughing up blood, shortness of breath, wheezing, fatigue, loss of appetite, unexplained weight loss, and chest pain. Symptoms that appear in the later stages of EGFR positive lung cancer may include hoarseness or changing voice, difficulty swallowing, eyelid drooping, facial swelling, nail abnormalities, bone, joint, and shoulder pain, and weakness.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for EGFR Positive Lung Cancer?
Depending on the stage of EGFR positive lung cancer as well as the specific mutation involved, there are a variety of options available. If the cancer has not spread and is in an early stage, individuals may be able to undergo surgery to completely remove the cancer. There are also a variety of drug options called EGFR inhibitors that prevent unregulated cell growth. Some examples of EGFR inhibitors include Afatinib (Gilotrif), Erlotinib (Tarceva), Gefitinib (Iressa), Osimertinib (Tagrisso), Dacomitinib (Vizimpro), and Necitumumab (Portrazza). Treatment plans, including the type of EGFR inhibitor used, are typically specialized based on the specific EGFR mutation. Individuals with EGFR positive lung cancer may also be able to take part in clinical trials that offer newer or more experimental treatments.
Who are the top EGFR Positive Lung Cancer Local Doctors?
Elite in EGFR Positive Lung Cancer
Elite in EGFR Positive Lung Cancer
Referral may be required

NYU Langone Hospitals

160 E 34th St, 
New York, NY 
212-731-5662
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Sabari is an Oncologist practicing medicine in New York, New York. Dr. Sabari is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Tissue Biopsy, and Thrombectomy.

Elite in EGFR Positive Lung Cancer
Elite in EGFR Positive Lung Cancer
Referral may be required

Interventional Radiology In San Jose

2589 Samaritan Dr, 
San Jose, CA 
408-426-4900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Heather Wakelee is an Oncologist practicing medicine in San Jose, California. Dr. Wakelee is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in EGFR Positive Lung Cancer
Dr. Hossein Borghaei
Oncology | Radiology | Hematology
Elite in EGFR Positive Lung Cancer
Dr. Hossein Borghaei
Oncology | Radiology | Hematology
Referral may be required

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
888-369-2427
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Hossein Borghaei is an Oncologist and a Radiologist practicing medicine in Philadelphia, Pennsylvania. Dr. Borghaei is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Borghaei is board certified in American Board Of Internal Medicine - Medical Oncology.

View All Doctors
What are the support groups for EGFR Positive Lung Cancer?
Groups such as EGFR Resisters (https://egfrcancer.org/) offer support for individuals with EGFR positive lung cancer. There are also support groups that focus more generally on non-small cell lung cancer: Cancer Support Community: Non-Small Cell Lung Cancer - https://www.cancersupportcommunity.org/non-small-cell-lung-cancer American Lung Association, Lung Cancer Support Groups - https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/patients/find-support/support-groups
What is the outlook (prognosis) for EGFR Positive Lung Cancer?
Many targeted treatments have been developed for EGFR positive lung cancer in recent years, which has given patients much more hope. Individuals who receive an early diagnosis and/or targeted treatments are likely to have the best outcomes.
What are the possible complications of EGFR Positive Lung Cancer?
Complications of EGFR positive lung cancer can include shortness of breath, fluid accumulation around the lung and in the chest (pleural effusion), coughing up blood (hemoptysis), pain, nausea, headache. There is also a chance that cancer can spread (metastasize) to other parts of the body through tissue, the lymph system, or blood.
When should I contact a medical professional for EGFR Positive Lung Cancer?
It is important to call your doctor if you have symptoms of lung cancer, chronic cough, coughing up blood, shortness of breath, wheezing, fatigue, loss of appetite, unexplained weight loss, and chest pain, especially if you smoke. After receiving a non-small cell lung cancer diagnosis, individuals can undergo genetic testing to identify any genetic abnormalities such as EGFR mutations.
What are the latest EGFR Positive Lung Cancer Clinical Trials?
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab v...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).
Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metas...

View All Clinical Trials